| ECG | Electro-Cardio-Graphy(-Gram); 심전도 = EKG 1. Conducting System Structu... |
|---|---|
| AER | abduction/external rotation; acoustic evoked response; acute exertional rhabdomyolysis; agranular en... |
| SR | sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat... |
| LU | left upper [limb]; loudness unit; Lupron; lytic unit |
| LyNeF | lytic nephritic factor |
| LU | Lytic Units |
|---|---|
| TLF | Trypanosome Lytic Factor |
| TRE | 12-(O-tetradecanoylphorbol-13-acetate response element |
| APRF | 3/acute phase response factor |
| CREB | 4/cAMP response element-binding protein |
| Mlt38 lytic transglycosylase | <enzyme> Active against poly(murnac-glcnac) strands Registry number: EC 2.4.- Synonym: membrane-bound lytic transglycosylase 38-kD, mlt38 protein, mlta gene product (26 Jun 1999) |
|---|---|
| direct lytic factor of cobra venom | A polypeptide of 62 residues; action on cells is similar to that of melittin in that it promotes disruption of membranes; used as an investigational antirheumatic agent. Synonym: cobra toxin, direct lytic factor of cobra venom. (05 Mar 2000) |
| direct lytic factors | most abundant proteins in cobra (naja of the elapids) venom; basic polypeptides of 57 to 62 amino acids with four disulfide bonds and a molecular weight of less than 7000; causes skeletal and cardiac muscle contracture, interferes with neuromuscular and ganglionic transmission, depolarises nerve, muscle and blood cell membranes, thus causing haemolysis. Synonym: cobramine a; cobramine b; cobra cytotoxin; gamma toxin; membrane-active polypeptide. (12 Dec 1998) |
| lytic | 1. Pertaining to lysis or to a lysin. 2. Producing lysis. Origin: Gr. Lysis = dissolution (18 Nov 1997) |
| lytic complex | <immunology> The large (2000 kD) cytolytic complex formed from complement C5b6789. See: complement. (18 Nov 1997) |
| lytic cycle | The general life cycle of a lytic virus, from infection of the host cell, hijacking of the host cells mechanisms, use of the host cells mechanisms to produce viral components, and assembly of the components into progeny viruses, to the destruction of the host cell by rupturing its plasma membrane (lysis) and the release of the progeny viruses so that they can spread and infect other cells. (09 Oct 1997) |
| lytic infection | The normal cycle of infection of a cell by a virus or bacteriophage, in which mature virus or phage particles are produced and the cell is then lysed. (18 Nov 1997) |
| lytic pathway | The steps in the method that a virus takes to complete a lytic cycle, including the production and assembly of progeny viruses with host cell machinery and the destruction of the host cell by rupturing its plasma membrane (lysis), releasing the progeny viruses in the process. (09 Oct 1997) |
| lytic phage | A bacteriophage (virus which infects bacteria) that can only follow the lytic pathway to completing its lytic cycle, and does not have the mechanisms to enter the lysogenic pathway. (09 Oct 1997) |
| lytic phase | A phase of the virus life cycleduring which the virus replicates within the host cell, releasing a new generation of viruses when the infectedcell lyses. (09 Oct 1997) |
| lytic virus | <virology> A virus which, as part of its life cycle, causes its host cells plasma membrane to rupture (to lyse). (09 Oct 1997) |
| anamnestic response | <immunology> Archaic term now replaced by such terms as secondary immune response, immune memory. (18 Nov 1997) |
| audiometry, evoked response | A form of electrophysiologic audiometry in which an analog computer is included in the circuit to average out ongoing or spontaneous brain wave activity. A characteristic pattern of response to a sound stimulus may then become evident. Evoked response audiometry is known also as electric response audiometry. (12 Dec 1998) |
| auditory brainstem response audiometry | An electrophysiologic measure of auditory function utilizing responses produced by the auditory nerve and the brainstem to repetitive acoustic stimuli. (05 Mar 2000) |
| biological response modifier | <pharmacology, oncology> A substance used in adjuvant therapy that takes advantage of the bodys own natural defense mechanisms to inhibit the growth of a tumour. (16 Dec 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|